Patents Assigned to Trident Pharmaceuticals, Inc.
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 8992940
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 31, 2015
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Agent for Treating Allergic or Hypersensitivity Condition
    Publication number: 20130345114
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Application
    Filed: January 18, 2013
    Publication date: December 26, 2013
    Applicant: TRIDENT PHARMACEUTICALS, INC.
    Inventor: TRIDENT PHARMACEUTICALS, INC.
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 8357372
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: January 22, 2013
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
  • Therapeutic Agents
    Publication number: 20120003267
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: June 27, 2011
    Publication date: January 5, 2012
    Applicant: Trident Pharmaceuticals, Inc.
    Inventors: Neil A. Williams, Timothy R. Hirst, Toufic O. Nashar
  • Vaccine
    Patent number: 7914791
    Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 29, 2011
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
  • THERAPEUTIC AGENTS
    Publication number: 20100136023
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: September 14, 2009
    Publication date: June 3, 2010
    Applicant: TRIDENT PHARMACEUTICALS, INC.
    Inventors: NEIL ANDREW WILLIAMS, TIMOTHY RAYMOND HIRST, TOUFIC OSMAN NASHAR
  • Methods for the prevention against or treatment of diabetes with ETXB and/or insulin
    Patent number: 7588763
    Abstract: This application relates to methods for modulating an immune response in a mammalian subject in need of prevention against or treatment of diabetes comprising the administration of EtxB and/or insulin.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 15, 2009
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Agent for treating allergic or hypersensitivity condition
    Patent number: 7208155
    Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: April 24, 2007
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock